Market Overview

UPDATE: Goldman Sachs Reiterates Neutral Rating, Raises PT on HCC Insurance Holdings After 4Q12 Earnings

Related HCC
Exelixis's Cabometyx Positive for First-Line Kidney Cancer
Exelixis Initiates Cabozantinib-Tecentriq Combination Trial

In a report published Friday, Goldman Sachs reiterated its Neutral rating on HCC Insurance Holdings (NYSE: HCC), and raised its price target from $37.00 to $40.00.

Goldman Sachs noted, “We update our estimates for HCC following the 4Q12 conference call. We remain Neutral-rated. The company beat our estimates due to higher reserve development and slightly better underlying profitability, but results were otherwise in line. We are revising our estimates slightly higher to reflect higher underlying profitability in the A&H and Professional Liability segments. Also, our investment income estimates are modestly higher due to a slightly larger investment portfolio than we previously estimated, as the company continues to utilize its low-cost revolving credit facility to fund share buybacks.”

HCC Insurance Holdings closed on Thursday at $39.74.

Latest Ratings for HCC

Jun 2017Morgan StanleyDowngradesOverweightEqual-Weight
May 2017RBC CapitalInitiates Coverage OnOutperform
May 2017BMO CapitalInitiates Coverage OnBuy

View More Analyst Ratings for HCC
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Price Target Analyst Ratings


Related Articles (HCC)

View Comments and Join the Discussion!